• Home
  • About IonChannelCentral

Ion channel News

Entries RSS | Comments RSS
  • Tags

    agonist amitiza Amlodipine Anesiva Angiotensin II AT1 antagonist AstraZeneca ca channel Calcium Channel chloride channel CIC-2 CIC2 cl channel Clevelox Clevidipine Cleviprex CV therapeutics Icagen Ion Channel KCa3.1 K Channel Licensing lidocaine lubiprostone Merck na channel Novartis phase II Potassium Channel preclinical Regulatory Research RU-0211 RU0211 Senicapoc Sodium channel SPI-0211 Sucampo takeda The Medicines Company TRPV1 UCB Vanilloid voltage gated VR1

Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery

Posted on July 17, 2008 by crimsoncanary
Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Filed under: Ion Channel | Tagged: Adlea, agonist, ALGRX-4975, ALGRX4975, Anesiva, phase II, TRPV1, Vanilloid, VR1

« Phase IIb results show Vernakalant effective in atrial fibrillation CV therapeutics announce FDA is continuing review of Ranexa for Angina »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • July 2008
      M T W T F S S
      « Jun   Aug »
       123456
      78910111213
      14151617181920
      21222324252627
      28293031  
  • Blogroll

    • CrimsonCanary.com
    • IonChannelCentral
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer